STORM Therapeutics and AlidaBio Announce Strategic Collaboration to Accelerate Development of Cancer Therapies Targeting RNA Modifications

STORM Therapeutics Ltd. (STORM), the clinical stage company pioneering cellular reprogramming through RNA modifications to treat disease, today announced a strategic collaboration with Alida ...
PharmaTimes

Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies

STORM Therapeutics has entered a new collaboration with US‑based AlidaBio to accelerate the development of cancer therapies that target RNA modifications.
Morningstar

AlidaBio Launches First Service Provider Partnership with Baylor College of Medicine's GARP Core to Offer Multiplexed RNA Modification Sequencing

SAN DIEGO, June 9, 2025 /PRNewswire/ -- Alida Biosciences, a leader in next-generation RNA modification analysis, is proud to announce its first official service provider: the Genomic and RNA ...
Medical Xpress

Genetic Phenomena: News and Research on RNA Editing

Science X Daily and the Weekly Email Newsletter are free features that allow you to receive your favorite sci-tech news updates in your email inbox ...
eLife

Fragile nucleosomes are essential for RNA Polymerase II to transcribe in eukaryotes

Nucleosomes are barriers to RNA Polymerase II (Pol II) transcribing along gene bodies in eukaryotes. We found that a fragile “tailless nucleosome” could be generated to resolve the Pol II pausing ...